Labcorp Posts 9.5 Percent Gain in Q2

Laboratory Corporation of America (NYSE:LH), a global leader in diagnostics and drug development, reported results for Q2 2025 on July 24, 2025. The earnings release highlighted strong GAAP revenue growth that beat consensus estimates, adjusted earnings per share (non-GAAP) that outpaced expectations, and an increase in adjusted operating margins. GAAP revenue came in at $3.53 billion versus the $3.486 billion expected by analysts, and adjusted earnings per share (non-GAAP) rose to $4.35 against a consensus estimate of $4.17. The company’s leadership described the quarter as one marked by double-digit topline growth and margin expansion in both its Diagnostics Laboratories and Biopharma Laboratory Services segments. Management raised full-year guidance for 2025, reflecting confidence in both underlying operational performance and forward momentum. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Laboratory Corporation of America is a multinational company specializing in diagnostic testing services and drug development support. It serves healthcare providers, hospitals, pharmaceutical companies, and patients globally. It processes over 700 million tests annually, employs about 70,000 people, and operates in around 100 countries.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool